Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Valganciclovir
Drug ID BADD_D02326
Description Valganciclovir hydrochloride (Valcyte, manufactured by Roche) is an antiviral medication used to treat cytomegalovirus infections. As the L-valyl ester of ganciclovir, it is actually a prodrug for ganciclovir. After oral administration, it is rapidly converted to ganciclovir by intestinal and hepatic esterases.
Indications and Usage Valganciclovir is an antiviral medication used for the treatment of cytomegalovirus infections.
Marketing Status approved; investigational
ATC Code J05AB14
DrugBank ID DB01610
KEGG ID D02495
MeSH ID D000077562
PubChem ID 135413535
TTD Drug ID D06GWF
NDC Product Code 69097-277; 31722-832; 50268-787; 60429-846; 70069-810; 71921-210; 27241-158; 55111-762; 61269-480; 0004-0038; 70010-051; 0904-6796; 63739-076; 68084-965; 71151-003
UNII GCU97FKN3R
Synonyms Valganciclovir | Ganciclovir L-valyl Ester | Ganciclovir L valyl Ester | Valcyt | Valganciclovir Hydrochloride | Valcyte
Chemical Information
Molecular Formula C14H22N6O5
CAS Registry Number 175865-60-8
SMILES CC(C)C(C(=O)OCC(CO)OCN1C=NC2=C1N=C(NC2=O)N)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Cytomegalovirus syndrome11.05.01.005---
Procedural complication12.02.05.005--
Post procedural complication12.02.05.018---
Disturbance in sexual arousal19.08.04.003---
Angiopathy24.03.02.007---
Blood alkaline phosphatase increased13.04.02.004--
Cardiac disorder02.11.01.003---
Connective tissue disorder10.04.04.026; 15.06.01.006---
Infestation11.09.01.001; 23.11.01.002---
Malnutrition14.03.02.004---
Mediastinal disorder22.09.03.001---
Mental disorder19.07.01.002---
Decreased appetite08.01.09.028; 14.03.01.005--
Erectile dysfunction19.08.04.001; 21.03.01.007--
Ill-defined disorder08.01.03.049---
Inner ear disorder04.04.02.002---
Blood disorder01.05.01.004---
Psychotic disorder19.03.01.002--
Hepatobiliary disease09.01.08.003---
Renal impairment20.01.03.010---
Device related infection08.07.01.005; 11.01.08.018--
Procedural pain08.01.08.009; 12.02.05.007---
Bone marrow failure01.03.03.005--
Oropharyngeal discomfort07.05.05.008; 22.12.03.015---
Oropharyngeal pain07.05.05.004; 22.12.03.016--
Pneumocystis jirovecii pneumonia11.03.07.005; 22.07.08.009---
Candida infection11.03.03.021--
Systemic infection11.01.08.050---
Anal incontinence07.01.06.029; 17.05.01.021--
Attention deficit hyperactivity disorder19.21.04.004---
The 7th Page    First    Pre   7 8    Next   Last    Total 8 Pages